A Survey on Adrenal Incidentaloma in Italy1
The DOI matches its Crossref record.
Abstract
The aim of this study was to perform a national survey on occasionally discovered adrenal masses [adrenal incidentalomas (AI)] under the auspices of the Italian Society of Endocrinology. This multicentric and retrospective evaluation of patients with AI includes 1096 cases collected in 26 centers between 1980 and 1995. Relevant information was obtained by means of a specifically tailored questionnaire. Of the 1096 forms received, 1004 were retained for final analysis. Patients were 420 males and 584 females, aged between 15-86 yr (median, 58 yr). Mass size (computed tomography measurement) ranged from 0.5-25 cm (median, 3.0 cm). Hormonal work-up demonstrated that 85% of the masses were nonhypersecretory, 9.2% were defined as subclinical Cushing's syndrome, 4.2% were pheochromocytomas, and 1.6% were aldosteronomas. Adrenalectomy was performed in 380 patients with removal of 198 cortical adenomas (52%), 47 cortical carcinomas (12%), 42 pheochromocytomas (11%), and other less frequent tumor types. Patients with carcinoma were significantly younger than patients with adenoma (median, 46; range, 17-84; vs. 57, 16-83 yr; P = 0.05). Adenomas were significantly smaller than carcinomas (3.5, 1-15 vs. 7.5, 2.6-25 cm; P < 0.001), and a cut-off at 4.0 cm had the highest sensitivity (93%) in differentiating between benign and malignant tumors. Hormonal work-up of patients with subclinical Cushing's syndrome showed low baseline ACTH in 79%, cortisol unsuppressibility after 1 mg dexamethasone in 73%, above normal urinary free cortisol in 75%, disturbed cortisol rhythm in 43%, and blunted ACTH response to CRH in 55%. Only 43% of patients with pheochromocytoma were hypertensive, and 86% showed elevated urinary catecholamines. All patients with aldosteronoma were hypertensive and had suppressed upright PRA. These results indicate that mass size is the most reliable variable in separating benign from malignant AI. Adrenalectomy should be recommended for AI greater than 4.0 cm because of the increased risk of malignancy, especially in young patients. Endocrine evaluation should be performed in all patients to identify silent states of hormone excess.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Self-citationSherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“Among autopsy and radiology series, the prevalence of AIs increases with age, showing a peak incidence in the fifth to seventh decades (Table 3 (39,40,42,46-84)).”
BackgroundResultInfluentialCortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas
Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3007 · Cited by 269
Bancos, I., Taylor, A. E., Chortis, V., Sitch, A. J., Jenkinson, C., Davidge-Pitts, C. J., Lang, K., Tsagarakis, S., Macech, M., Riester, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30218-7 · Cited by 250
Self-citationCushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
“patients, who represent a population in which Cushing’s syndrome is more common.(22,23)”
Deutschbein, T., Reimondo, G., Di Dalmazi, G., Bancos, I., Patrova, J., Vassiliadi, D. A., Nekić, A. B., Debono, M., Lardo, P., Ceccato, F., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00100-0 · Cited by 205
Self-citationApproach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Prete, A., Subramanian, A., Bancos, I., Chortis, V., Tsagarakis, S., Lang, K., Macech, M., Delivanis, D. A., Pupovac, I. D., Reimondo, G., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-1737 · Cited by 154
Self-citationClinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
Manger, W. M., & Gifford, R. W. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.01452.x · Cited by 143
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
Därr, R., Kuhn, M., Bode, C., Bornstein, S. R., Pacak, K., Lenders, J. W. M., & Eisenhofer, G. (2017) · Endocrine · doi:10.1007/s12020-017-1300-y · Cited by 105
Yi, X., Guan, X., Chen, C., Zhang, Y., Zhang, Z., Li, M., Liu, P., Yu, A., Long, X., Liu, L., et al. (2018) · Journal of Cancer · doi:10.7150/jca.26356 · Cited by 87
Bernini, G. P., Moretti, A., Oriandini, C., Bardini, M., Taurino, C., & Salvetti, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602459 · Cited by 87
“Patients with adrenal incidentalomas, that is, clinically unapparent adrenal masses incidentally detected after imaging studies for unrelated reasons (Mantero et al, 2000; Mansmann et al, 2004), were carefully selected for this study.”
BackgroundMethodChemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis
Platzek, I., Sieron, D., Plodeck, V., Borkowetz, A., Laniado, M., & Hoffmann, R.-T. (2019) · European Radiology · doi:10.1007/s00330-018-5626-5 · Cited by 66
The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.
Grossrubatscher, E., Vignati, F., Possa, M., & Loli, P. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343941 · Cited by 52
Park, J., De Luca, A., Dutton, H., Malcolm, J. C., & Doyle, M.-A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00090 · Cited by 46
Ahn, S. H., Kim, J. H., Baek, S. H., Kim, H., Cho, Y. Y., Suh, S., Kim, B.-J., Hong, S., Koh, J.-M., Lee, S. H., et al. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.4.501 · Cited by 43
“001) in the SIE cohort.(8) The scattered plots in the COAR cohort also showed that the cutoff value of 3.”
InfluentialThe lateralizing asymmetry of adrenal adenomas
Hao, M., Lopez, D., Luque-Fernandez, M. A., Cote, K., Newfield, J., Connors, M., & Vaidya, A. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00034 · Cited by 40
Primary aldosteronism in patients with adrenal incidentaloma: is screening appropriate for everyone?
Stavropoulos, K., Imprialos, K. P., Katsiki, N., Petidis, K., Kamparoudis, A., Petras, P., Georgopoulou, V., Finitsis, S., Papadopoulos, C., Athyros, V. G., et al. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13291 · Cited by 23
Metadata
- Authors
- Mantero, F., Terzolo, M., Arnaldi, G., Osella, G., Masini, A. M., Alı̀, A., Giovagnetti, M., Opocher, G., & Angeli, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-02
- Volume
- 85
- Issue
- 2
- Pages
- 637-644
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2940488023
- Cited by
- 272
- References
- 0
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.